Rapid Diagnostics for HIV and Hepatitis
Recruitment status was: Recruiting
The purpose of this study is to determine the efficacy of two rapid diagnostic tests in plasma, venipuncture whole blood, and fingerstick whole blood. The clinical performance of Multiplo HBc/HIV/HCV will be determined by comparing the results with patient infected status for HIV-1/2 (human immunodeficiency viruses 1 and 2), HBV (hepatitis B virus) and HCV (hepatitis C virus). The clinical performance of Reveal HBsAg will be determined by comparing the results with patient infected status for HBV.
Subject participation in the study will consist of a single one-hour visit, at which time blood samples will be drawn for testing with the investigational devices and with approved comparator assays. The test results, which are the outcome of the study, will be obtained only once, at the time of this visit.
|HIV Infections Hepatitis B Infections Hepatitis C Infections||Device: Multiplo HBc/HIV/HCV and Reveal HBsAg|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg|
- Clinical performance of Reveal HBsAg and Multiplo HBc/HIV/HCV [ Time Frame: At single study visit ]
For each enrolled subject, Multiplo HBc/HIV/HCV and Reveal HBsAg devices will be used to test finger stick whole blood, venipuncture whole blood, and plasma samples. Plasma will also be tested using separate algorithms of FDA approved assays to determine patient infected status for HIV-1/2, hepatitis B, and hepatitis C.
The performance of Reveal HBsAg will be determined relative to patient infected status for hepatitis B for each matrix assessed. The performance of Multiplo HBc/HIV/HCV will be determined relative to patient infected status for each of hepatitis B, HIV-1/2, and hepatitis C.
|Study Start Date:||May 2014|
|Estimated Study Completion Date:||August 2015|
|Estimated Primary Completion Date:||August 2015 (Final data collection date for primary outcome measure)|
Experimental: Diagnostic: Multiplo HBc/HIV/HCV + Reveal HBsAg
Subjects tested with investigational devices and approved comparator assay algorithms for HIV and hepatitis B and C.
Device: Multiplo HBc/HIV/HCV and Reveal HBsAg
All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
The objective of this study is to determine the performance characteristics of two rapid diagnostic tests.
Approximately 3000-4500 subjects in total will be enrolled in the study into four different study populations. In Population 1, which is "at risk" group of about 2000-3000 subjects, roughly 2/3 will be individuals who are at risk of infection with HIV or hepatitis B or C, or who have signs or symptoms of hepatitis. Approximately 500 of these individuals are expected to be known HIV-positive individuals.
The remaining three study populations will be comprised of individuals with known infection with HIV (Population 1A, ~500 individuals), HBV (Population 1B, ~500 individuals), and HCV (Population 1C, ~500 individuals).
Both Multiplo HBc/HIV/HCV and Reveal HBsAg will be used to test finger stick whole blood, venous whole blood and plasma samples from each subject in Population 1. Plasma samples (repository or fresh) will be used to fulfill the requirements for Populations 1A, 1B, and 1C.
For all enrolled subjects, the plasma sample will be tested with the following FDA-approved assays: EIA for anti-HIV-1/2, anti-HCV, anti-HBc total, anti-HBc IgM, anti-HBs, and HBsAg. The efficacy of Multiplo will be determined by comparing the results with patient infected status for HIV-1/2, HBV and HCV. The efficacy of Reveal will be determined by comparing the results with patient infected status for HBV.
The primary analysis will involve comparison of Multiplo HBc/HIV/HCV and Reveal HBsAg results for each of the test markers (anti-HIV-1/2, anti-HCV, anti-HBc, and HBsAg), in each sample matrix (finger stick whole blood, venous whole blood and plasma) with the patient infected status as determined by separate algorithms for HIV, HBV, and HCV. The percent positive and percent negative agreement will be determined relative to patient infected status for each marker and sample type, with corresponding two-sided 95% confidence intervals.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02190305
|United States, California|
|Keck School of Medicine - LAUSC||Not yet recruiting|
|Los Angeles, California, United States, 90089-9239|
|Contact: Peter Kerndt, MD 310-905-2871 email@example.com|
|United States, Florida|
|SCFLD Hepatology Diagnostic Research Laboratory||Recruiting|
|Miami, Florida, United States, 33136|
|Contact: Maria D DeMedina 305-243-6500|
|Principal Investigator: Eugene R Schiff|
|United States, Minnesota|
|Minneapolis Medical Research Foundation||Recruiting|
|Minneapolis, Minnesota, United States, 55404|
|Contact: Fred Apple, MD 612-873-6888 firstname.lastname@example.org|
|Principal Investigator: Fred Apple, MD|
|United States, New York|
|NYC Dept Health & Mental Hygiene||Recruiting|
|New York, New York, United States, 11101|
|Contact: Brett Wolfson-Stofko, PhD 718-292-7718 ext 471 email@example.com|
|Contact: Fabienne Laraque, MD 347-396-7415 firstname.lastname@example.org|
|Principal Investigator:||Eugene Schiff, MD||University of Miami|
|Principal Investigator:||Peter Kerndt, MD||University of Southern California - Los Angeles|
|Principal Investigator:||Fabienne Laraque, MD||New York City Department of Health and Mental Hygiene|